Taxanes and New hormonal agents: How they work?
|
|
- Quentin Powell
- 5 years ago
- Views:
Transcription
1 Taxanes and New hormonal agents: How they work?
2 Taxanes
3
4 Microtubules are highly dynamic cytoskeletal fibres that are composed of tubulin of which are crucial to mitosis and cell division. Jordan Nat Rev Cancer 2004
5 Microtubules functions Cell shape Transport of vesicles Mitochondrial function Cell signalling Cell lldivision i i and mitosis i
6 Emerging mechanistic scenarios of the effects of taxane-based chemotherapy on microtubules and androgen receptor signaling. Mistry S J, and Oh W K Mol Cancer Ther 2013;12:
7 Abiraterone acetate
8 17 hydroxylase lyase Agarwal Fut Oncol 2010 modified
9 enzalutamide
10
11 Testosterone & AR: Their role in PC
12 Logothetis Cancer Disc 2013
13
14
15 Seruga Nat Rev Clin Oncol 2011
16
17
18 ES Antonarakis Oral presentation June 1, 2014
19
20
21 S Antonarakis Oral presentation June 1, 2014
22 Azad Poster Highlights sessione May 30, 2014
23 ARv7, which lacks the hinge region, did not co sediment with microtubules, unlike ARv567. Nuclear accumulation and transcriptional activity of ARv7 was unaffected by taxane treatment.
24 chaarted
25
26 Sweeney Abs #LBA2 Plenary session June 1, 2014
27
28
29
30 C. Sweeney Abs #LBA2 Plenary session June 1, 2014
31
32 Chemotherapy in hormone sensitive Issues Rationale Selection criteria Side effects PC Magnitude of the results Additional data
33 Sweeney Abs #LBA2 Plenary session June 1, 2014
34 Outline Level Eighth Outline Level Selection criteria? Outline Level Ninth Outline LevelFare clic per modificare stili del testo dello schema Breast cancer Prostate cancer Click to edit the outline text format ER/PGR pos vs neg DRE Clinical/biological Second Outline Level criteria (St.Gallen Third OutlineLevel guidelines) Ki67 HER2 status ER status Fourth Outline Level Fifth Outline Level Sixth Outline Level Seventh Click to edit the outline text format GS PSA Second Outline Level Third OutlineLevel Fourth Outline Level Fifth Outline Level Sixth Outline Level Seventh
35 CHAARTED definition of the risk High ihvolume Visceral mets and/or 4 bone mets (at last 1 beyond pelvis and 4 bone mets (at last 1 beyond pelvis and vertebral column)
36 CHAARTED definition of the risk High ihvolume Visceral mets and/or 4 bone mets (at last 1 beyond pelvis and vertebral column) MJ Morris Discussant Plenary session June 1, 2014
37 Side effects CHAARTED Anemia 1 Thrombocytopenia Neutropenia 12 Febrile neutropenia 6 Fatigue 4
38 Side effects CHAARTED TAX 327 Anemia 1 5 Thrombocytopenia 1 Neutropenia Febrile neutropenia 6 3 Fatigue 4 5
39
40 Will chemo became the new standard for hormonosensitive PC pts? t? YES (fora quote of pts waiting moreaccurate selection criteria) Are the presented data enough? NO (additional analyses are needed)
41 Chemo in early stages
42 Neo adjuvant (surgery) down organ confin ed author year Drug GS PSA T # T PSA mfu %RFb mar gin Pettaway 2000 KET+DOX/VBL+E + TAB (duration: 12 wks) >8 > NR NR Clark 2001 VP16+E x 21 d/ 4 w x 3 >8 >15 2B Hussain* 2003 DOC/3w + E 280 TID x 3 6 >8 >15 >2b (#10) Dreicer 2004 DOC w x 6 >8 >15 2b 3 29 NR Beer 2004 DOC+MITOX w x 4 (phase I) > 4+3 >15 2c 3a 21 NR 20/2 1 Konety 2004 Carbo AUC 6 + PCT 180 mg/sqm+ EMP 280 TID + LHRH A x 4 6 Febbo 2005 DOC w x > ( MRI) 76 NR NR >8 > NR NR NR NR
43 Neo adjuvant (XRT) author year Drug GS PSA T # mfu %RFb Ben Josef 2001 VP16+E x 2 XRT + E >7 > (3y DFS) Hussain* 11 XRT 2003 DOC/3w + E 280 TID x 3 6 >8 >15 >2b (2 HT) Zelefsky 2004 VBL+E x 2 XRT + VBL+E x 1 >8 >20 > (5y)
44 Adjuvant Pilepich [RTOG 81 12] (Am J Clin Oncol 1986) XRT ( Gy) CTX+DOX+CDDP Schmidt (Eur Urol1996) XRT or surgery E 600 mg/sqm/d x 2 years CTX 1 g/sqm/3w x 2 years observation
45 CALGB neo Phase III Study of Radical Prostatectomy Alone Versus adj Neoadjuvant Docetaxel in High Risk Localized Prostate t Cancer RTOG 9902 adj Phase III randomized d study of androgen suppression and radiotherapy with or without subsequent paclitaxel, estramustine, and etoposide in patients with localized high-risk prostate cancer Click to edit the outline text format SWOG 9921 adj Adjuvant Androgen Deprivation Versus Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High Risk Prostate Cancer Patients Following Radical Prostatectomy: Phase III Second Outline Level XRP6976J/3501 adj A Multicenter, Open-Label, Randomized, Phase III Trial FRE-FNCLCC- GETUG-12/0203 neo adj Third Outline Level Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD - leuprolide acetate) in Combination with TAXOTERE Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients at High Risk of Relapse After Radical Prostatectomy Fourth Outline Level Fifth Outline Level Phase III randomized study of neoadjuvant releasing factor agonist therapy and antiandrogen therapy with or without docetaxel and estramustine in patients with locally ll advanced d prostate t cancer or with a high h risk of relapse
46
47
48 Given the lack of phase III trials, there is limited data regarding the role of (neo) adjuvant chemotherapy with or without ADT prior to RP in localized or locally advanced prostate cancer
49 K Fizazi Oral presentation June 1, 2014
50 K Fizazi Oral presentation June 1, 2014
51 K Fizazi Oral presentation June 1, 2014
52 K Fizazi Oral presentation June 1, 2014
53
54
55
Philip Kantoff, MD Dana-Farber Cancer Institute
CHEMOTHERAPY FOR MCRPC Philip Kantoff, MD Dana-Farber Cancer Institute Harvard Medical School 1 Disclosure of Financial Relationships With Any Commercial Interest Name Nature of Financial Commercial Interests
More informationRationale for Multimodality Therapy for High Risk Localized Prostate Cancer
Rationale for Multimodality Therapy for High Risk Localized Prostate Cancer 100 80 60 Cancer Death Rates for Men, US 1930-2002 Rate Per 100,000 Lung William K. Oh, M.D. 40 Stomach Colon & rectum Prostate
More informationSESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia
SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia Divisione di Oncologia Medica Unità Tumori Genitourinari SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract
More informationmcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE
mcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE IL CARCINOMA PROSTATICO, UNA MALATTIA ETEROGENEA? RAZIONALE E RISULTATI DEL TRATTAMENTO CHEMIOTERAPICO ASSOCIATO ALL
More informationStrategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer
Strategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer Daisaku Hirano, MD Department of Urology Higashi- matsuyama Municipal Hospital, Higashi- matsuyama- city, Saitama- prefecture,
More informationEarly Chemotherapy for Metastatic Prostate Cancer
Early Chemotherapy for Metastatic Prostate Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Smilow Cancer Center Yale University Medical Center Disclosure Consultant: Sanofi Aventis, Celgene,
More informationPROSTATA MULTIDISCIPLINARITA IN URO-ONCOLOGIA INTEGRAZIONE TERAPIA SISTEMICA-TRATTAMENTO LOCALE. Dr.ssa Ori Ishiwa Dr Sergio Bracarda
15 anno di fondazione del GUONE MULTIDISCIPLINARITA IN URO-ONCOLOGIA Aviano, 10 settembre 2010 INTEGRAZIONE TERAPIA SISTEMICA-TRATTAMENTO LOCALE PROSTATA Dr.ssa Ori Ishiwa Dr Sergio Bracarda UOC Oncologia
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More information2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC
Ronald de Wit Erasmus MC Cancer Institute The Netherlands 2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC Disclosures Sanofi ; research grant support, consultancy and speaker fees Astellas;
More informationCancer de la prostate métastatique: prise en charge précoce
Cancer de la prostate métastatique: prise en charge précoce Stéphane Oudard, MD, PhD Georges Pompidou Hospital, Oncology Department, Paris, France stephane.oudard@egp.aphp.fr SAGB.CAB.14.08.0382c 3/02/2016
More informationADT vs chemo + ADT as initial treatment for advanced prostate cancer
ADT vs chemo + ADT as initial treatment for advanced prostate cancer By Hussein Khaled Prof. Medical Oncology Cairo University Possible Levels of Prostate Cancer At Diagnosis Local-Regional Disease Spread
More informationUpdates in Prostate Cancer Treatment 2018
Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant
More informationSequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC)
Sequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC) Amit Bahl Consultant Oncologist Bristol Cancer Institute Clinical Director Spire Specialist Care Centre UK Disclosures Advisory
More informationADVANCES IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER. ALICIA K. MORGANS, MD, MPH Associate Professor of Medicine Northwestern University, USA
ADVANCES IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER ALICIA K. MORGANS, MD, MPH Associate Professor of Medicine Northwestern University, USA MAY 2018 DISCLAIMER Please note: The views expressed within
More informationPerspective on endocrine and chemotherapy agents. Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr. Sternberg has received research funding for
More informationSequencing treatment for metastatic prostate cancer
11 Sequencing treatment for metastatic prostate cancer SOPHIE MERRICK, STYLIANI GERMANOU, ROGER KIRBY AND SIMON CHOWDHURY In the past 10 years there have been significant advances in the understanding
More informationP.A. 65 anni In terapia anti ipertensiva da 4 anni. Non ha mai eseguito il PSA Da qualche mese dolore alla spalla sx che sia
Dicembre 2012 P.A. 65 anni In terapia anti ipertensiva da 4 anni (sartanico) Non ha mai eseguito il PSA Da qualche mese dolore alla spalla sx che sia accentua coi movimenti Si rivolge al curante che prescrive
More informationSession 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy
Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy October- 2015 ESMO 2004 October- 2015 Fyraftensmøde 2 2010 October- 2015 Fyraftensmøde 3 SWOG 9916 OS
More informationChemohormonal Therapy For Prostate Cancer. What is old, is new again!
Chemohormonal Therapy For Prostate Cancer What is old, is new again! Mount Tremblant January 20, 2017 Kala S. Sridhar MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital Head, GU Medical Oncology
More informationProstate Cancer in comparison to Radiotherapy alone:
Prostate Cancer in comparison to Radiotherapy alone: 1 RTOG 86-10 (2001) 456 patients with > a-goserelin 2 month before RTand during RT + Cyproterone acetate (1 month) vs b-pelvic irradiation (50 gy) +
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer SAMO Masterclass 4 th March 2016 Aurelius Omlin Conflicts of interest Advisory Rolle: Astra Zeneca, Astellas, Bayer, Janssen, Pfizer, Sanofi Aventis Research support: TEVA, Janssen
More informationOptimizing Outcomes in Advanced Prostate Cancer
Optimizing Outcomes in Advanced Prostate Cancer Module 3: Focus on Recent CRPC Guidelines and Advanced Hormone-Sensitive Disease Sébastien J. Hotte, MD, MSc (HRM), FRCPC Medical Oncologist and Head, Phase
More informationCurrent role of chemotherapy in hormone-naïve patients Elena Castro
Current role of chemotherapy in hormone-naïve patients Elena Castro Spanish National Cancer Research Centre Lugano, 17 October 2017 Siegel, Ca Cancer J Clin,2017 Buzzoni, Eur Urol, 2015 -Aprox 15-20% of
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationChallenging Cases. With Q&A Panel
Challenging Cases With Q&A Panel Case Studies Index Patient #1 Jeffrey Wieder, MD Case # 1 72 year old healthy male with mild HTN Early 2011: Preop bone scan and pelvic CT = no mets Radical prostatectomy
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in nonorchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationWhat will change for men with advanced prostate cancer in the next 24 months? ESO Observatory: Perspective on endocrine and chemotherapy agents
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr.Sternberg has received research funding for
More informationMetastatic prostate carcinoma. Lee Say Bob July 2017
Metastatic prostate carcinoma Lee Say Bob July 2017 Scenario A 58 year old gentleman presents with PSA 200 ng/ml with hard prostate and bone mets. LUTS but upper tracts are normal with normal RP. history
More informationManagement of Prostate Cancer
Management of Prostate Cancer An ESMO Perspective Alan Horwich Conflicts of Interest Disclosure Alan Horwich I have no personal conflicts of interest relating to prostate cancer. European Incidence and
More informationHigh-Risk Localized Prostate Cancer: A Case for Early Chemotherapy Martin Gleave and W. Kevin Kelly
NUMBER NOVEMBER VOLUME 23 d 32 d 10 2005 JOURNAL OF CLINICAL ONCOLOGY R E V I E W A R T I C L E High-Risk Localized Prostate Cancer: A Case for Early Chemotherapy Martin Gleave and W. Kevin Kelly From
More informationOligometastasis. Körperstereotaxie bei oligo-metastasiertem Prostatakarzinom wann und wie in Kombination mit Systemtherapie?
Körperstereotaxie bei oligo-metastasiertem Prostatakarzinom wann und wie in Kombination mit Systemtherapie? Daniel M. Aebersold 09. Dezember 2016 Oligometastasis JCO, 1995 1 Oligometastasis: Chance for
More informationSessione platinum series Best Papers
Sessione platinum series Best Papers ormonoterapia G. Cartenì Direttore U.O.S.C. di Oncologia Medica A.O.R.N. A. Cardarelli Napoli 1 2 Enzalutamide Enzalutamide: PREVAIL Studio di fase III Patients with
More informationJoelle Hamilton, M.D.
Joelle Hamilton, M.D. www.urologycentersalabama.com Case Presentation: CRPC, Rising PSA 70 yo healthy, fit, active man post RALP 8 years prior with rising PSA Rising PSA from 0.02 nadir to 3.4 thus ADT
More informationHormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering
> Hormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific
More informationA Forward Look at Options for. In Prostate Cancer
A Forward Look at Options for Prostate Cancer Charles J Ryan, MD Associate Professor of Medicine Helen Diller Family Comprehensive Cancer Center University of California, San Francisco UC 1 SF UC SF Castration
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationNOVITÀ IN TEMA DI NEOPLASIA DELLA PROSTATA L ALGORITMO TERAPEUTICO NEL CARCINOMA DELLA PROSTATA METASTATICO SENSIBILE ALLA CASTRAZIONE
NOVITÀ IN TEMA DI NEOPLASIA DELLA PROSTATA L ALGORITMO TERAPEUTICO NEL CARCINOMA DELLA PROSTATA METASTATICO SENSIBILE ALLA CASTRAZIONE S.S. Oncologia Medica Genitourinaria Outline 1. Clinical case 2. Chemotherapy
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer January 13, 2017 Sindu Kanjeekal MD FRCPC Medical Oncology and Hematology Regional Systemic Quality Lead Erie St Clair Adjunct Professor Schulich School of Medicine and University
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More informationRecent Progress in Management of Advanced Prostate Cancer
Review Article [1] April 15, 2005 By Philip W. Kantoff, MD [2] Androgen-deprivation therapy, usually with combined androgen blockade, is standard initial treatment for advanced prostate cancer. With failure
More informationBoard Review 2017: Prostate Cancer. Dana Rathkopf, MD Associate Attending
Board Review 2017: Prostate Cancer Dana Rathkopf, MD Associate Attending www.mskcc.org The Paradox of Prostate Cancer High prevalence in the general population: over diagnosis of clinically insignificant
More informationSUMMARY. 3. Emerging understanding of mechanisms of resistance to current treatments
SUMMARY 1. Discuss the active agents in prostate cancer currently available in Australia 2. Celebrate the growing role for Prostate Medical Oncologists in Multi Disc Teams active treaments overall survival
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in non orchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationProstate cancer update: Dr Robert Huddart Cancer Clinic London
Prostate cancer update: 2013 Dr Robert Huddart Cancer Clinic London Recent developments Improved imaging New radiotherapy technologies Radiotherapy for advanced disease Intermittent hormone therapy New
More informationTreatment of Advanced Prostate Cancer
Treatment of Advanced Prostate Cancer Wm. Kevin Kelly, DO Associate Professor of Medicine and Surgery Yale University Yale University School of Medicine Advanced Prostate Cancer Metastatic Cancer Prostate
More informationCurrent UW/SCCA GU Oncology Clinical Trials Updated 01/25/2010
Neoadjuvant Non-Metastatic Current UW/SCCA GU Oncology Clinical Trials Gleason Stage PSA Design Type Route Active surveillance PASS 3 Active Surveillance for pts w/ Active T1 2 NA Visit Seattle q6 months
More informationAdvanced Prostate Cancer. SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin
Advanced Prostate Cancer SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin aurelius.omlin@kssg.ch Conflicts of Interest Research Support: TEVA, Janssen Advisory Rolle: Astra Zeneca, Astellas,
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationNCCN Guidelines for Prostate Cancer V Web teleconference 06/17/16 and 06/30/17
Guideline Page and Request PROS-1 Submission from Myriad Genetic Laboratories, Inc. Request addition of recommendation for genetic risk assessment/testing to the Initial Clinical Assessment algorithm for
More informationHormone therapy works best when combined with radiation for locally advanced prostate cancer
Hormone therapy works best when combined with radiation for locally advanced prostate cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Introduction Introduction 1/3 of patients
More informationNational Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA
More informationFrancesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
Focus sulla malattia metastatica ormonosensibile (mhspc) ADT e Chemioterapia: quando e a chi? Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
More informationSOGUG meeting New drugs after docetaxel chemotherapy in patient with mcrpc
SOGUG meeting New drugs after docetaxel chemotherapy in patient with mcrpc Stéphane OUDARD, MD, PhD Head of the Oncology department Georges Pompidou Hospital, Paris France University Rene Descartes, Paris
More informationSecondary Hormonal therapies in mcrpc
Secondary Hormonal therapies in mcrpc Ravindran Kanesvaran Consultant,Division of Medical Oncology National Cancer Centre Singapore 1 Disclosures Research Support/P.I. Sanofi Consultant Major Stockholder
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationClinical Management Guideline for Planning and Treatment. The process to be followed when a course of chemotherapy is required to treat:
Clinical Management Guideline for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: PROSTATE CANCER Patient information given at each stage following
More informationMAMTA PARIKH, MD, MS CHALLENGING CASE #2: GU CANCER & STATE OF THE ART: CASTRATION RESISTANT PROSTATE CANCER
MAMTA PARIKH, MD, MS CHALLENGING CASE #2: GU CANCER & STATE OF THE ART: CASTRATION RESISTANT PROSTATE CANCER NO RELEVANT FINANCIAL RELATIONSHIPS IN THE PAST TWELVE MONTHS BY PRESENTER OR SPOUSE/PARTNER.
More informationHormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer
Review Article Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer Federica Recine, Cora N. Sternberg Department of Medical Oncology, San Camillo and Forlanini Hospitals,
More informationUrologic Oncology: Seminars and Original Investigations 30 (2012) 3 15
Urologic Oncology: Seminars and Original Investigations 30 (2012) 3 15 Review article The multi-disciplinary management of high-risk prostate cancer Jonathan C. Picard, M.D. a, *, Ali-Reza Golshayan, M.D.
More informationIn autopsy, 70% of men >80yr have occult prostate ca
Prostate Cancer UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Two randomized trials showed survival benefit of adding docetaxol to ADT in fit man with very high localized disease
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationUPDATE ON RECENT CUTTING-EDGE TRIALS: TREATMENTS NOW AVAILABLE FOR NEWLY DIAGNOSED mhspc PATIENTS
UPDATE ON RECENT CUTTING-EDGE TRIALS: TREATMENTS NOW AVAILABLE FOR NEWLY DIAGNOSED mhspc PATIENTS Dr. Neal Shore, Carolina Urologic Research Centre, USA Assoc. Prof. Neeraj Agarwal, Huntsman Cancer Institute,
More informationwww.drpaulmainwaring.com Figure 1 Androgen action Harris W P et al. (2009) Nat Clin Pract Urol doi:10.1038/ncpuro1296 Figure 2 Mechanisms of castration resistance in prostate cancer Harris W P et al. (2009)
More informationAdjuvant Docetaxel and Abbreviated Androgen Deprivation Therapy in Patients with High Risk Prostate Cancer
The Open Prostate Cancer Journal, 21, 3, 9914 99 Open Access Adjuvant Docetaxel and Abbreviated Androgen Deprivation Therapy in Patients with High Risk Prostate Cancer Jose G. Bazan, Christopher R. King,
More informationProstate Cancer. Dr. Andres Wiernik 2017
Prostate Cancer Dr. Andres Wiernik 2017 Objectives YES!!! 1. Epidemiology 2. Biology or Natural History of Prostate Cancer 3. Treatment NO!!! 1. Prostate Cancer Screening - controversies Which is the most
More information8/31/ ) Intermittent androgen deprivation in androgen-sensitive PCa. 1) Alpharadin (Ra223) in CRPC with bone metastases
Bruce J. Roth, M.D. Clinical Trials: Medivation, Oncogenix 1) Alpharadin (Ra223) in CRPC with bone metastases 2) Enzalutamide (MDV-31) in CRPC and prior docetaxel 3) Abiraterone in chemo-naïve CRPC 4)
More informationCME Baseline Curriculum Report
CME Baseline Curriculum Report October 14, 2010 For CME Activity: Managing Advanced Prostate Cancer in the Community Setting: A Case-based Curriculum Supported by an independent educational grant from
More informationASCO 2012 Genitourinary tumors
ASCO 2012 Genitourinary tumors Post ASCO Bern 14-06-2012 Dr. med. Richard Cathomas leitender Arzt Onkologie, KSGR, Chur Renal cell cancer Changes in first line treatment? Prostate cancer 3 positive phase
More informationSecond line hormone therapies. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
Second line hormone therapies Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More informationInitial hormone therapy (and more) for metastatic prostate cancer
Initial hormone therapy (and more) for metastatic prostate cancer Silke Gillessen, MD Medical Oncology Kantonsspital St.Gallen Switzerland silke.gillessen@kssg.ch Conflicts of interest Speakers Bureau
More informationOpen clinical uro-oncology trials in Canada
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES
More informationOverview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
More informationTNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 The problem with TNBC 1. Generally more aggressive 2. ONLY chemotherapy 3. No other
More informationThe Role of the Medical Oncologist in the Treatment of Prostate Cancer. Alireza saadat hematologist and oncologist
The Role of the Medical Oncologist in the Treatment of Prostate Cancer Alireza saadat hematologist and oncologist When should you see an oncologist? High risk localized disease Rising PSA after local therapy
More informationESMO SUMMIT MIDDLE EAST 2018
ESMO SUMMIT MIDDLE EAST 2018 14 Years of progress in Prostate Cancer Standards of Care and new targets Name Ronald de Wit 6-7 April 2018, Dubai, UAE CONFLICT OF INTEREST DISCLOSURE Sub-title Sanofi Roche
More informationThe State of Cancer Care: Reflections from the 2017 ASCO Annual Meeting
The State of Cancer Care: Reflections from the 2017 ASCO Annual Meeting Margaret Tempero, M.D. Director, Pancreas Center, University of California, San Francisco Editor-in-Chief, Journal of the National
More informationRadiation with oral hormonal manipulation for non-metastatic, intermediate or high risk prostate cancer in men 70 and older or with comorbidities
Radiation with oral hormonal manipulation for non-metastatic, intermediate or high risk prostate cancer in men 70 and older or with comorbidities Prostate cancer is predominately a disease of older men,
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Relevant Disclosure I have received research support
More informationManagement of castration resistant prostate cancer after first line hormonal therapy fails
Management of castration resistant prostate cancer after first line hormonal therapy fails Simon Crabb Senior Lecturer in Medical Oncology University of Southampton WHAT ARE THE AIMS OF TREATMENT? Cure?
More informationFocus sulla malattia metastatica ormonosensibile (mhspc) ADT e Terapia ormonale: quando e a chi?
Focus sulla malattia metastatica ormonosensibile (mhspc) ADT e Terapia ormonale: quando e a chi? Paolo Andrea Zucali Dipartimento di Oncologia HUMANITAS CANCER CENTER Rozzano - Milano AGENDA Literature
More informationProstate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE
Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE Low risk localised PSA < 10 ng/ml and Gleason score 6, and clinical stage T1 - T2a Intermediate risk localised PSA 10-20 ng/ml, or Gleason
More informationChemotherapy in the Treatment of Prostate Cancer The Past, the Present, and the Future
chemotherapy Chemotherapy in the Treatment of Prostate Cancer The Past, the Present, and the Future Srinath Sundararajan, MD, and Nicholas Vogelzang, MD Abstract Chemotherapy is an important treatment
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD, Mary J. Mackenzie, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES CISPLATIN-BASED
More informationX, Y and Z of Prostate Cancer
X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios
More informationפ א ר מ ה P H A R x M A
פ א ר מ ה P H A R x M A הביטאון לענייני תרופות ותראפיה ISRAEL DRUG BULLETIN Vol. 19, Bulletin No. 107 June-July 2012 Also in the Bulletin: Degarelix for Advanced Hormone-Dependent Prostate Cancer NEW TREATMENT
More informationNew Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일
New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일 Castrate-Resistant Prostate Cancer (CRPC) Current standard therapy Androgen receptor (AR) in CRPC New systemic therapies Hormonal therapy
More informationHormonotherapy of advanced prostate cancer
Annals of Oncology 16 (Supplement 4): iv80 iv84, 2005 doi:10.1093/annonc/mdi913 Hormonotherapy of advanced prostate cancer P. Pronzato & M. Rondini Department of Oncology, Felettino Hospital, La Spezia,
More informationECF chemotherapy for liver metastases due to castration-resistant prostate cancer
Original research ECF chemotherapy for liver metastases due to castration-resistant prostate cancer Shruti Gupta, BHSc; * Kylea Potvin, MD; * D. Scott Ernst, MD; * Frances Whiston; Eric Winquist, MD, MSc,
More informationNuevas perspectivas en el cáncer de próstata hormono-sensible metastásico Tratamiento actual del cáncer de próstata. Situación de Enzalutamida
Nuevas perspectivas en el cáncer de próstata hormono-sensible metastásico Tratamiento actual del cáncer de próstata. Situación de Enzalutamida Dr Pablo Maroto Hospital Sant Pau Dr Pablo Maroto Hospital
More informationPossible Risk Factors Associated with Relapse in Patients Treated with Neoadjuvant Chemohormonal Therapy for High Risk Prostate Cancer
6 The Open Prostate Cancer Journal, 2011, 4, 6-13 Open Access Possible Risk Factors Associated with Relapse in Patients Treated with Neoadjuvant Chemohormonal Therapy for High Risk Prostate Cancer R. S.
More informationNovel treatment for castration-resistant prostate cancer
Novel treatment for castration-resistant prostate cancer Cora N. Sternberg, MD, FACP Chair, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Treatment options for patients
More informationLancet 2008; 372 : CDF. N Engl J Med Aug 28;349(9): J Clin Oncol May 15;19(10): Cancer Nov 1;113(9):2471-7
Tumour Group: UROLOGY Renal Palliative Sunitinib 1 st line therapy Lancet. 1999 Jan 2;353(9146):14-7. Pazopanib 1 st line therapy J Clin Oncol. 2010 28(06):1061-1068 Everolimus 2 nd or 3 rd line in adv./metas.rcc
More informationDespite stage migration, a signifıcant number of patients
Why Chemotherapy Should be Given Early for Men with Metastatic Prostate Cancer Leonel F. Hernandez-Aya, MD, and Maha Hussain, MD, FACP, FASCO OVERVIEW Metastatic hormone-sensitive prostate cancer (mhspc)
More informationMETASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
More informationUntil 2004, CRPC was consistently a rapidly lethal disease.
Until 2004, CRPC was consistently a rapidly lethal disease. the entry in systemic disease is declared on a an isolated PSA recurrence after local treatment so!!! The management of CRPC and MCRPC is different
More informationClinical Case Conference
Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3
More informationMedical Treatments for Prostate Cancer
Medical Treatments for Prostate Cancer Ian F Tannock MD, PhD Daniel E Bergsagel Professor of Medical Oncology, Princess Margaret Hospital and University of Toronto March 17, 2005 Brampton 1 A hypothetical
More information